These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1560148)

  • 1. The economic implications of bioengineered mastitis control.
    Miles H; Lesser W; Sears P
    J Dairy Sci; 1992 Feb; 75(2):596-605. PubMed ID: 1560148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of partial budgeting to determine the economic outcome of Staphylococcus aureus intramammary infection reduction strategies in three Ohio dairy herds.
    Hoblet KH; Miller GY
    J Am Vet Med Assoc; 1991 Sep; 199(6):714-20. PubMed ID: 1955362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against bovine mastitis in the New Zealand context: what is the best way forward?
    Denis M; Wedlock DN; Lacy-Hulbert SJ; Hillerton JE; Buddle BM
    N Z Vet J; 2009 Jun; 57(3):132-40. PubMed ID: 19521461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and costs of a control program for an epizootic of Staphylococcus aureus mastitis.
    Goodger WJ; Ferguson G
    J Am Vet Med Assoc; 1987 May; 190(10):1284-7. PubMed ID: 3108206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against Staphylococcus aureus mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147.
    Twomey DP; Wheelock AI; Flynn J; Meaney WJ; Hill C; Ross RP
    J Dairy Sci; 2000 Sep; 83(9):1981-8. PubMed ID: 11003227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cow-specific treatment of clinical mastitis: an economic approach.
    Steeneveld W; van Werven T; Barkema HW; Hogeveen H
    J Dairy Sci; 2011 Jan; 94(1):174-88. PubMed ID: 21183029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological responses and evaluation of the protection in dairy cows vaccinated with staphylococcal surface proteins.
    Merrill C; Ensermu DB; Abdi RD; Gillespie BE; Vaughn J; Headrick SI; Hash K; Walker TB; Stone E; Kerro Dego O
    Vet Immunol Immunopathol; 2019 Aug; 214():109890. PubMed ID: 31378218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of vaccination and antimicrobial treatment to eliminate chronic intramammary Staphylococcus aureus infections in dairy cattle.
    Smith GW; Lyman RL; Anderson KL
    J Am Vet Med Assoc; 2006 Feb; 228(3):422-5. PubMed ID: 16448371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioeconomic modeling of intervention against clinical mastitis caused by contagious pathogens.
    Halasa T
    J Dairy Sci; 2012 Oct; 95(10):5740-9. PubMed ID: 22863098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic losses from and the national research program on mastitis in the United States.
    Blosser TH
    J Dairy Sci; 1979 Jan; 62(1):119-27. PubMed ID: 379057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimate of the economic impact of mastitis: A case study in a Holstein dairy herd under tropical conditions.
    Guimarães JLB; Brito MAVP; Lange CC; Silva MR; Ribeiro JB; Mendonça LC; Mendonça JFM; Souza GN
    Prev Vet Med; 2017 Jul; 142():46-50. PubMed ID: 28606365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of E. coli mastitis is mainly determined by cow factors.
    Burvenich C; Van Merris V; Mehrzad J; Diez-Fraile A; Duchateau L
    Vet Res; 2003; 34(5):521-64. PubMed ID: 14556694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle.
    Chang BS; Moon JS; Kang HM; Kim YI; Lee HK; Kim JD; Lee BS; Koo HC; Park YH
    Vaccine; 2008 Apr; 26(17):2081-91. PubMed ID: 18387721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field trials of a vaccine against bovine mastitis. 2. Evaluation in two commercial dairy herds.
    Calzolari A; Giraudo JA; Rampone H; Odierno L; Giraudo AT; Frigerio C; Bettera S; Raspanti C; Hernández J; Wehbe M; Mattea M; Ferrari M; Larriestra A; Nagel R
    J Dairy Sci; 1997 May; 80(5):854-8. PubMed ID: 9178125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production effects related to mastitis and mastitis economics in dairy cattle herds.
    Seegers H; Fourichon C; Beaudeau F
    Vet Res; 2003; 34(5):475-91. PubMed ID: 14556691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial budget of the discounted annual benefit of mastitis control strategies.
    Allore HG; Erb HN
    J Dairy Sci; 1998 Aug; 81(8):2280-92. PubMed ID: 9749395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A partial budget model to estimate economic benefits of lactational treatment of subclinical Staphylococcus aureus mastitis.
    Swinkels JM; Hogeveen H; Zadoks RN
    J Dairy Sci; 2005 Dec; 88(12):4273-87. PubMed ID: 16291618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of mastitis: facts and perception.
    Huijps K; Lam TJ; Hogeveen H
    J Dairy Res; 2008 Feb; 75(1):113-20. PubMed ID: 18226298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial budget analysis of vaccinating dairy cattle against coliform mastitis with an Escherichia coli J5 vaccine.
    DeGraves FJ; Fetrow J
    J Am Vet Med Assoc; 1991 Aug; 199(4):451-5. PubMed ID: 1917656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcus aureus antigens and challenges in vaccine development.
    Middleton JR
    Expert Rev Vaccines; 2008 Aug; 7(6):805-15. PubMed ID: 18665778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.